Thus, the observed increase in IL-22 production coupled with decreased IL-17A and TNFα with SR3335 highlight the benefits of targeting RORα in chronic inflammatory diseases like IBD where such actions would prove beneficial to patients. The gene discussed is IL22; the disease is inflammatory bowel disease.